Beta2-agonist increases skeletal muscle interleukin 6 production and release in response to resistance exercise in men

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Standard

Beta2-agonist increases skeletal muscle interleukin 6 production and release in response to resistance exercise in men. / Hostrup, Morten; Knudsen, Jakob Grunnet; Maag Kristensen, Caroline; Jessen, Søren; Pilegaard, Henriette; Bangsbo, Jens.

I: Scandinavian Journal of Medicine & Science in Sports, Bind 32, Nr. 7, 2022, s. 1099-1108.

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Harvard

Hostrup, M, Knudsen, JG, Maag Kristensen, C, Jessen, S, Pilegaard, H & Bangsbo, J 2022, 'Beta2-agonist increases skeletal muscle interleukin 6 production and release in response to resistance exercise in men', Scandinavian Journal of Medicine & Science in Sports, bind 32, nr. 7, s. 1099-1108. https://doi.org/10.1111/sms.14171

APA

Hostrup, M., Knudsen, J. G., Maag Kristensen, C., Jessen, S., Pilegaard, H., & Bangsbo, J. (2022). Beta2-agonist increases skeletal muscle interleukin 6 production and release in response to resistance exercise in men. Scandinavian Journal of Medicine & Science in Sports, 32(7), 1099-1108. https://doi.org/10.1111/sms.14171

Vancouver

Hostrup M, Knudsen JG, Maag Kristensen C, Jessen S, Pilegaard H, Bangsbo J. Beta2-agonist increases skeletal muscle interleukin 6 production and release in response to resistance exercise in men. Scandinavian Journal of Medicine & Science in Sports. 2022;32(7):1099-1108. https://doi.org/10.1111/sms.14171

Author

Hostrup, Morten ; Knudsen, Jakob Grunnet ; Maag Kristensen, Caroline ; Jessen, Søren ; Pilegaard, Henriette ; Bangsbo, Jens. / Beta2-agonist increases skeletal muscle interleukin 6 production and release in response to resistance exercise in men. I: Scandinavian Journal of Medicine & Science in Sports. 2022 ; Bind 32, Nr. 7. s. 1099-1108.

Bibtex

@article{006c1985795c4204877eb99039a8bdd1,
title = "Beta2-agonist increases skeletal muscle interleukin 6 production and release in response to resistance exercise in men",
abstract = "Objective: Several tissues produce and release interleukin-6 (IL-6) in response to beta2-adrenergic stimulation with selective agonists (beta2-agonists). Moreover, exercise stimulates muscle IL-6 production, but whether beta2-agonists regulate skeletal muscle production and release of IL-6 in humans, in association with exercise remains to be clarified. Thus, we investigated leg IL-6 release in response to beta2-agonist salbutamol in lean young men at rest and in recovery from resistance exercise.Design: The study employed a randomized controlled crossover design, where 12 men ingested either salbutamol (16 mg) or placebo for 4 days, followed by the last dose (24 mg) administered 1½ h before exercise. Arterial and femoral venous plasma IL-6 as well as femoral artery blood flow was measured before and ½-5 h in recovery from quadriceps muscle resistance exercise. Furthermore, vastus lateralis muscle biopsies were collected ½ and 5 h after exercise for determination of mRNA levels of IL-6 and Tumor Necrosis Factor (TNF)-α.Results: Average leg IL-6 release was 1.7-fold higher (p=0.01) for salbutamol than placebo, being 138±76 and 79±66 pg∙min-1 (mean±SD) for salbutamol and placebo, respectively, but IL-6 release was not significantly different between treatments within specific sampling points at rest and after exercise. Muscle IL-6 mRNA was 1.5 and 1.7-fold higher (p=0.001) for salbutamol than placebo ½ and 5 h after exercise, respectively, whereas no significant treatment differences were observed for TNF-α mRNA.Conclusions: Beta2-adrenergic stimulation with high doses of the selective beta2-agonist salbutamol, preceeded by 4 consecutive daily doses, induces transcription of IL-6 in skeletal muscle in response to resistance exercise and increases muscle IL-6 release in lean individuals.",
keywords = "Faculty of Science, Beta-adrenoceptor, Beta2-adrenoceptor, Beta2, SABA, Cytokine",
author = "Morten Hostrup and Knudsen, {Jakob Grunnet} and {Maag Kristensen}, Caroline and S{\o}ren Jessen and Henriette Pilegaard and Jens Bangsbo",
note = "This article is protected by copyright. All rights reserved.",
year = "2022",
doi = "10.1111/sms.14171",
language = "English",
volume = "32",
pages = "1099--1108",
journal = "Scandinavian Journal of Medicine & Science in Sports",
issn = "0905-7188",
publisher = "Wiley-Blackwell",
number = "7",

}

RIS

TY - JOUR

T1 - Beta2-agonist increases skeletal muscle interleukin 6 production and release in response to resistance exercise in men

AU - Hostrup, Morten

AU - Knudsen, Jakob Grunnet

AU - Maag Kristensen, Caroline

AU - Jessen, Søren

AU - Pilegaard, Henriette

AU - Bangsbo, Jens

N1 - This article is protected by copyright. All rights reserved.

PY - 2022

Y1 - 2022

N2 - Objective: Several tissues produce and release interleukin-6 (IL-6) in response to beta2-adrenergic stimulation with selective agonists (beta2-agonists). Moreover, exercise stimulates muscle IL-6 production, but whether beta2-agonists regulate skeletal muscle production and release of IL-6 in humans, in association with exercise remains to be clarified. Thus, we investigated leg IL-6 release in response to beta2-agonist salbutamol in lean young men at rest and in recovery from resistance exercise.Design: The study employed a randomized controlled crossover design, where 12 men ingested either salbutamol (16 mg) or placebo for 4 days, followed by the last dose (24 mg) administered 1½ h before exercise. Arterial and femoral venous plasma IL-6 as well as femoral artery blood flow was measured before and ½-5 h in recovery from quadriceps muscle resistance exercise. Furthermore, vastus lateralis muscle biopsies were collected ½ and 5 h after exercise for determination of mRNA levels of IL-6 and Tumor Necrosis Factor (TNF)-α.Results: Average leg IL-6 release was 1.7-fold higher (p=0.01) for salbutamol than placebo, being 138±76 and 79±66 pg∙min-1 (mean±SD) for salbutamol and placebo, respectively, but IL-6 release was not significantly different between treatments within specific sampling points at rest and after exercise. Muscle IL-6 mRNA was 1.5 and 1.7-fold higher (p=0.001) for salbutamol than placebo ½ and 5 h after exercise, respectively, whereas no significant treatment differences were observed for TNF-α mRNA.Conclusions: Beta2-adrenergic stimulation with high doses of the selective beta2-agonist salbutamol, preceeded by 4 consecutive daily doses, induces transcription of IL-6 in skeletal muscle in response to resistance exercise and increases muscle IL-6 release in lean individuals.

AB - Objective: Several tissues produce and release interleukin-6 (IL-6) in response to beta2-adrenergic stimulation with selective agonists (beta2-agonists). Moreover, exercise stimulates muscle IL-6 production, but whether beta2-agonists regulate skeletal muscle production and release of IL-6 in humans, in association with exercise remains to be clarified. Thus, we investigated leg IL-6 release in response to beta2-agonist salbutamol in lean young men at rest and in recovery from resistance exercise.Design: The study employed a randomized controlled crossover design, where 12 men ingested either salbutamol (16 mg) or placebo for 4 days, followed by the last dose (24 mg) administered 1½ h before exercise. Arterial and femoral venous plasma IL-6 as well as femoral artery blood flow was measured before and ½-5 h in recovery from quadriceps muscle resistance exercise. Furthermore, vastus lateralis muscle biopsies were collected ½ and 5 h after exercise for determination of mRNA levels of IL-6 and Tumor Necrosis Factor (TNF)-α.Results: Average leg IL-6 release was 1.7-fold higher (p=0.01) for salbutamol than placebo, being 138±76 and 79±66 pg∙min-1 (mean±SD) for salbutamol and placebo, respectively, but IL-6 release was not significantly different between treatments within specific sampling points at rest and after exercise. Muscle IL-6 mRNA was 1.5 and 1.7-fold higher (p=0.001) for salbutamol than placebo ½ and 5 h after exercise, respectively, whereas no significant treatment differences were observed for TNF-α mRNA.Conclusions: Beta2-adrenergic stimulation with high doses of the selective beta2-agonist salbutamol, preceeded by 4 consecutive daily doses, induces transcription of IL-6 in skeletal muscle in response to resistance exercise and increases muscle IL-6 release in lean individuals.

KW - Faculty of Science

KW - Beta-adrenoceptor

KW - Beta2-adrenoceptor

KW - Beta2

KW - SABA

KW - Cytokine

U2 - 10.1111/sms.14171

DO - 10.1111/sms.14171

M3 - Journal article

C2 - 35460295

VL - 32

SP - 1099

EP - 1108

JO - Scandinavian Journal of Medicine & Science in Sports

JF - Scandinavian Journal of Medicine & Science in Sports

SN - 0905-7188

IS - 7

ER -

ID: 304056474